Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
FMCN -SOLD Short this stock is like shooting fish in the barrel.MC 2.2 B rev 80 MM,lol.I shorted 2000 shares this AM @ 55.51
http://finance.yahoo.com/q/hp?s=FMCN
Nice ,i'll wait for a pull back .11-13.
PTSC i sold into strenght today.
I still think we'll have a big correction soon with the huge deficits ,raising interest,oil .
I Sold short 2500 shares of ZOLT 14.5
1000 MRVl 68.6 and 200 GOOG 357 today.
XDSL .41/.415
I can't wait for the big news.It 's holding pretty nice with a solid base .003..the upside is incredible big 100-500% .IMO
Agreed i'm out too for a little profit.
I'll be at the gate,lol.
XDSl is @ .375 .This will pop once the news hit the wire.IMo
I'm in XDSL .365
mPhase Technologies' Nanobattery Achieves Breakthrough in Portable Power; Joint development with Lucent Technologies Bell Labs yields the first fully assembled working nano-based battery prototype
Business Wire - February 09, 2006 13:07
LITTLE FALLS, N.J. & MURRAY HILL, N.J., Feb 09, 2006 (BUSINESS WIRE) -- mPhase Technologies (OTCBB:XDSL) and Lucent Technologies Bell Labs (NYSE:LU) today reported that their jointly developed nano-based "smart" battery prototype has proven it can store and convert energy on demand. This practical confirmation of the theory behind the technology is a major milestone in the product development process.
In a test conducted at Bell Labs' Murray Hill, N.J. facility, the development team demonstrated that the first fully assembled prototype device could generate enough power on demand to light a light-emitting diode (LED). The prototype is based on a novel nanostructured architecture pioneered at Bell Labs.
"We are pleased that the mPhase-Bell Labs team has surmounted many technical obstacles to make this theory into a working prototype," said Ron Durando, CEO mPhase Technologies. "This reinvention of the battery is addressing a major market need for portable, programmable power."
The demonstration, including the lighting of the LED, was captured on video by a production team from ScienCentral, a service that provides video reports on scientific breakthroughs to TV stations and the general public. The footage is viewable at: http://www.sciencentral.com.
The new generation of reserve power cells is based on a Bell Labs discovery that electrolyte will stay atop nano-textured surfaces until stimulated to flow, thereby triggering a reaction producing electricity. The "electrowetting" process in effect can permit activation of the batteries when required, yielding a very long shelf life. Batteries based on this technology have the potential to deliver far longer shelf life than existing battery technology.
About mPhase Technologies, Inc.
mPhase Technologies Inc. (OTC: XDSL) develops and commercializes next-generation telecommunications and nanotechnology solutions, delivering novel systems to the marketplace that advance functionality and reduce costs. The company, awarded the 2005 Frost & Sullivan Excellence in Technology Award and the Nano 50 Award from NASA Nanotech Briefs, is bringing nanotechnology out of the laboratory and into the market with a planned innovative long life power cell. Additionally, the company is working on prototype ultra-sensitive magnetometers that promise up to a 1,000-fold increase in sensitivity as compared with available uncooled sensors. More information is available at the mPhase Web site at www.mPhaseTech.com
About Bell Labs and Lucent Technologies
Bell Labs is the leading source of new communications technologies. It has generated more than 30,000 patents since 1925 and has played a pivotal role in inventing or perfecting key communications technologies, including transistors, digital networking and signal processing, lasers and fiber-optic communications systems, communications satellites, cellular telephony, electronic switching of calls, touch-tone dialing, and modems. Bell Labs scientists have received six Nobel Prizes in Physics, nine U.S. National Medals of Science and eight U.S. National Medals of Technology. For more information about Bell Labs, visit its Web site at www.bell-labs.com.
Lucent Technologies designs and delivers the systems, services and software that drive next- generation communications networks. Backed by Bell Labs research and development, Lucent uses its strengths in mobility, optical, software, data and voice networking technologies, as well as services, to create new revenue-generating opportunities for its customers, while enabling them to quickly deploy and better manage their networks. Lucent's customer base includes communications service providers, governments and enterprises worldwide. For more information on Lucent Technologies, which has headquarters in Murray Hill, N.J., USA, visit www.lucent.com.
Safe Harbor Statement
This news release contains forward-looking statements related to future growth and earnings opportunities. Such statements are based upon certain assumptions and assessments made by management of both companies mentioned in this press release in light of current conditions, expected future developments and other factors they believe to be appropriate. Actual results may differ as a result of factors over which the companies have no control.
SOURCE: mPhase Technologies
Media:
TMI
Sam Gronner, 201-592-7896
sam@technovative.com
or
Investors:
CEOCast
Ken Sgro, 212-732-4300
or
Lucent Technologies
Peter Benedict, 908-582-7710 (office)
pbenedict@lucent.com
I got some @1.02 and under .
I missed the boat,lol.
NEws should be hitting the wire anytime soon.IMo
I'll wait for under a dollar
Siri -I wouldn't touch the over bloat pig.It will take them a few years for the fundamentals to catch up with the MC by that time KVHI superior tech will crush both SIRI and XM with satellite TV.IMO
Siri -I wouldn't touch the over bloat pig.It will take them a few years for the fundamentals to catch up with the MC by that time KVHI superior tech will crush both SIRI and XM with satellite TV.IMO
I'm out of RWC as of yesterday for over 300% with 6 digits profit.
Ot I've been accumulating IMMG and will get for similar result .Gl
Do your own DD ..
http://www.investorshub.com/boards/board.asp?board_id=3781
http://ragingbull.lycos.com/mboard/boards.cgi?board=IMMG&read=10437
It's ready for the next leg up .BIDS are building up.
I'm in MSSI
.MSSI Achieves 238% Record Revenue Increase for January 2006
Business Wire - February 08, 2006 12:49
VIENNA, Va., Feb 08, 2006 (BUSINESS WIRE) -- MSSI (OTCBB:MSSI), an established provider of medical personnel, technology services and homeland security products to government and commercial clients, announced record revenue achievement for the month of January.
MSSI reported that it achieved record sales of $1.87 million for the first month of the year. Last year the company reported revenue of $553,957 in January 2005, representing an increase of 238% from 2005 to 2006. The record increase in revenue is primarily attributed to shared revenues and increased demand from MSSI's newly acquired Nurses Onsite Corporation (NOC) subsidiary. The peak in revenue is critical for MSSI, as it is poises itself for further growth this year.
MSSI's President and CEO, Dr. B.B. Sahay, stated earlier this year in a shareholder letter: "One of our primary goals in 2006 is to become profitable. We believe we have made some significant strides with the acquisition of Nurses PRN (now Nurses Onsite) and the successful integration of our management teams. We believe that this integration has added to MSSI the depth and breadth of talent that we need to execute our vision - which is to become a national provider of specialty medical staff in cities across the country and to increase our shareholder value through disciplined, responsible and profitable management."
Dr. Sahay further added, "We are pleased with the results demonstrated so far from Nurses Onsite and look forward to continued growth in our newer markets. We are seeing strong demand in all of our locations and are excited to start off the year in the right direction."
Robert Murphy, Chief Operating Officer of MSSI said, "While our impressive January numbers reflect slight seasonality in certain markets, we are very encouraged by the increases in non-seasonal offices. The strong demand, coupled with our newer cost efficient recruiting techniques, is proving our model to be both scalable and rapidly executable."
More information about MSSI-TeleScience International, Inc. may be found at: www.telescience.com.
More information about Nurses PRN may be found at: www.nurses-prn.com.
For MSSI-TeleScience inquiries, e-mail: investmentrelations@telescience.com.
About MSSI-TeleScience
In operation since 1992, MSSI-TeleScience International, Inc. is a provider of long-term medical personnel, homeland security and technology services to federal, state and local government agencies and to the private sector. The company's Medical Services Division has operations in 22 states servicing hospital and medical facilities with a complete range of medical staff, including doctors, nurses and technicians. The company holds multiple long-term contracts, including those with the U.S. Army, the U.S. Department of Health and Human Services and the state of California.
The company's Technology Division provides systems integration and information technology services to the federal government, as well as emergency equipment, decontamination products, vehicles and supplies to state and local governments.
MSSI-TeleScience International currently has over 200 employees and continues to grow its staff and contracts. For more information, visit the company's website at www.telescience.com.
About Nurses Onsite Corp.
Nurses Onsite is a provider of nurse staffing services to acute care facilities nationwide. The company operates a network of 13 staffing locations in 9 states, serving over 200 hospitals. These locations primarily focus on placing per diem nurses on an "as needed" basis to hospitals facing a critical shortage of staff nurses. Based in West Palm Beach, Florida, Nurses Onsite employs over 1,200 nurses and 30 executive, management and administrative staff. Having grown organically since inception in 2002, the company has been invited into new markets by some of the nation's largest hospital chains because of its cost efficient streamlined delivery model.
Nurses Onsite plans to expand services rapidly by leveraging its recruiting technology in the recently launched National Recruiting Center. For more information, visit the company's website at www.nurses-prn.com.
Legal Notice Regarding Forward-Looking Statements: "Forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 may be included in this news release. These statements relate to future events or our future financial performance. These statements are only predictions and may differ materially from actual future results or events. MSSI-TeleScience disclaims any intention or obligation to revise any forward-looking statements whether as a result of new information, future developments or otherwise. There are important risk factors that could cause actual results to differ from those contained in forward-looking statements, including, but not limited to, risks associated with changes in general economic and business conditions (including in the information technology and financial information industry), actions of our competitors, the extent to which we are able to develop new services and markets for our services, the time and expense involved in such development activities, the level of demand, market acceptance of our services
IMMG
Future of Advertising
With the biggest day in the advertising market recently occurring, it may be necessary to highlight this business and update the investor
on the latest happenings of this industry. The Super Bowl, which is known for its excessive hype, is also recognized as the pinnacle event for marketers and advertising professionals alike. According to many reports, more than 90 million Americans watched the game, with many more worldwide. And surprisingly, many watched just for its commercials. Each year advertisers are given the opportunity to display their products and services to one of the largest audiences in the world. However, this opportunity does not come cheap. For Super Bowl XL, ABC Broadcasting charged $2.4 million for each 30-second commercial time slot, a cool $80,000 dollars a second or 2.6c per American viewer.
There are definitely other avenues to explore when trying to reach a target audience, and one of the new concepts that could be considered much cheaper while still achieving its goal is the "out of home" digital media concept.
If you've ever seen a futuristic movie, digital media is depicted as a normal part of life. Not that these movies
can predict the future, but they have been known to give viewers a glimpse of what could lie ahead. Talking billboards that recognize individuals, tablet-like newspapers with news and ads that change over time, and computer controlled voices in stores that ask if you need assistance with shopping are just some of the concepts that have been displayed. The world is not near that far advanced yet, but it could be heading in that direction.
For now, the most advanced "out of home" digital media is changing billboards, mobile advertising trucks, and LCD monitors in areas of high traffic, and one company that possesses all of these is Impart Media Group (IMMG).
Impart recently announced the acquisition of all the assets of Marlin Capital Partners II, LLC d/b/a InTransit
Media, a privately-held advertising and marketing services company with locations in Florida and New York. IMMG paid $500,000 in cash and delivered 146,762 shares of their common stock but feel they received the better end of the deal. InTransit transferred its exclusive rights to provide digital advertising services to the Port Authority of New York and New Jersey for the Port Authority's PATHVision broadcasting
system. The Pathvision system 270 displays in 13 transit stations in the NY Metro/New Jersey area, delivering over 6 million monthly viewer impressions to its audience.
Regarding the acquisition, CEO David Lott said, "We purchased In Transit Media at a competitive price and feel like we can extract value that was undiscovered. We are the oldest most experienced ‘Out of home' digital advertising company in the US and I see value here in Transit Media."
One setback though has been the slowed adoption of this type of advertising but Lott explains, "It's really
the traditional media buyer just beginning to move outside his comfort zone. When the media buyers try a new market they are stepping out and taking a risk. We think more media buyers will step out and discover this growing advertising space."
One company has already succeeded in this industry internationally. Focus Media Holdings, Limited (FMCN) operates the largest "out of home" advertising network in China using up to 30,000 audiovisual flat-panel displays. The reason they've succeeded is that Chinese companies and consumers were not accustomed to legacy advertising methods and often are the first to adopt the latest technology. Another example of this phenomenon would be the cell phone growth in Germany. Europeans adopted cell phones after the fall of the Berlin Wall because the reunited country had not invested in standard telephone lines and instead adopted the latest technology well ahead of their American counterparts. We believe that may be a parallel phenomena.
In any event, IMMG has purchased an interesting asset in PATHVision, and is setting its sights on other areas of congestion in the city that never sleeps. LaGuardia and JFK airports are especially enticing with their lengthy delays for travelers, providing ample opportunity for the gazing eye to spot an advertisement of interest. In the changing landscape of the advertising industry, investors might need to follow the Impart name and know who's changing the nature of information delivery
http://www.knobias.com/clipreport/clipreport.pdf
maybe too early but it was a good trade ,lol.
I only traded on momo only and didn't hold it overnite.Ty for the warning
Nice ...I'm out of CTDC @ 9.46 for 1500+ profits .
CTDC Float is only 1.5 MM shares.The Shorts get caught with their pants dwn .IMO
Not too big only 3K shares @ 8.97
In CTDC .
I pass on that.
Sniffex, Inc. Announces Agreement to Sell Military Equipment
Monday February 6, 6:29 pm ET
IRVING, TX--(MARKET WIRE)--Feb 6, 2006 -- Sniffex, Inc. ("Sniffex") (Other OTC:SNFX.PK - News), producers of Sniffex, an explosives and weapons detection device, announced today the completion of an agreement for products now sold to all branches of the US military by TR Gear, a Plano, TX, company. The agreement provides Sniffex with the rights to sell any of TR Gear's military equipment through its worldwide agent network. The Company stated that access to these products is the beginning of a long term strategy to acquire additional products for its agent network to sell. Products will be acquired through numerous distribution agreements and company acquisitions
Impart Media Group Acquires InTransit Media
PR Newswire - February 07, 2006 08:02
Acquisition Expands Digital Signage Business to PATH System in New York/New Jersey
SEATTLE, Feb 07, 2006 /PRNewswire-FirstCall via COMTEX/ -- IMPART Media Group, Inc. (OTC Bulletin Board: IMMG), an innovator in the content, creation and management of out-of-home digital advertising and information networks, today announced that it has purchased all assets of Marlin Capital Partners II, LLC d/b/a InTransit Media, a privately-held advertising and marketing services company located in Pompano Beach, Florida and New York City. Included in the asset purchase are the exclusive rights to provide digital signage and out-of-home digital advertising services for the PATHVision digital network. The PATHVision system includes more than 277 displays throughout 13 transit stations in New York City and New Jersey that provide advertisements and informational spots for travelers. IMPART Media Group, Inc. (IMPART), will continue to market the PATHVision system under the InTransit Media name, as it continues the rapid expansion of its travel network strategy.
Laird Laabs, president and co-founder of IMPART stated, "We are extremely pleased to add the PATHVision system to our growing portfolio of solutions for the out-of-home digital advertising sector, and believe this acquisition will provide IMPART with a highly visible advertising opportunity to one of the most desirable demographic segments in the country." Laabs added, "As we mobilize our aggressive expansion in this rapidly growing advertising space, we will continue our mission to seek out additional strategic and viable market opportunities like those provided by InTransit Media and PATHVision."
PATHVision is a digital signage system ideally suited for the growing out-of-home advertising sector. It provides information to a captive audience delivering more than 72 million annual viewer impressions. The PATH transit system carries over 70% of the passengers entering New York City by rail from New Jersey; of those, 52% are Professional-Managerial, and over 59% are in the 25-to-44 age range. This premier advertising venue also includes rail travelers passing through the new state-of-the-art PATH facility under construction at the World Trade Center. This high quality demographic audience represents a prime market for advertisers. The PATHVision system provides up-to-date news, rail schedules, weather and related marketing messages and is already a successful venue with a marquee list of advertisers and sponsors including The Wall Street Journal, Barron's, Embassy Suites, HBO Sports, Washington Mutual, among others.
IMPART believes that with the addition of its current and planned marketing resources, it will be able to greatly increase the revenue potential for PATHVision and will continue to provide the Port Authority with a state-of-the-art revenue generating partnership. Additional information about the PATHVision system and InTransit Media may be found at www.intransitmedia.com.
"The terms of the acquisition and the relationships developed with Charles Eissa, Founder and Chief Operating Officer of InTransit Media, provided IMPART with two distinct opportunities-the ability to expand its out-of-home advertising model, and an investor partner opportunity," stated Joe F. Martinez IMPART Chairman and Chief Financial Officer. "In the final analysis," Martinez stated, "the InTransit team was so impressed with IMPART and its market opportunities, that it recommended that Marlin Capital managing partner Mike Brauser, make an investment in IMPART by taking stock in lieu of cash for the majority of the purchase price in the transaction -- a true testament to the merits of a successful negotiation and trust in the abilities of each partner."
About IMPART Media Group, Inc.
IMPART Media Group, Inc., (OTC Bulletin Board: IMMG), headquartered in Seattle, Washington, is a rapidly expanding digital signage leader in the emerging out-of-home media sector. The company is growing through a consolidation strategy that includes acquiring the industries best and brightest talent and most advanced solutions to create a broad, integrated one-stop communications media company focused on digital signage and networked advertising offerings for leading brands in industries such as retail, grocery, banking, restaurants, hospitality, government and public spaces, among others. The company's digital media solutions enable the simultaneous delivery of video content to a variety of remote audiences in real time, allowing for immediate customization of messages through a centralized network operations center. More information please visit: www.impartmedia.com.
This release includes projections of future results and "forward-looking statements" as that term is defined in Section 27A of the Securities Act of 1933 as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934 as amended (the "Exchange Act"). All statements that are included in this release, other than statements of historical fact, are forward-looking statements. Although the respective management of IMPART Media Group, Inc. believes that the expectations reflected in these forward-looking statements are reasonable, they can give no assurance that such expectations will prove to have been correct. Important factors that could cause actual results to differ materially from the expectations are disclosed in this release, including, without limitation, in conjunction with those forward-looking statements contained in this release.
Public Relations: Cheryl Isen, Principal, Isen and Company
(425) 222-0779 or Cheryl@IsenandCo.com
Investor Relations: Rick Lutz, LC Group
(404) 261-1196 or LCGroup@mindspring.com
THE STEELERSSSSSSSSSSSSSSSSSSSSS made me beaucoup monies $15K .
Nice base for a launching pad when the news hit the wire.
HEPH 6.23/6.24 load up for next week run.
I'm back in HEPH for 5 K shares 6.17 .
Mass. lawmakers looking at buying Hollis-Eden radiation drug (HEPH)
By Val Brickates Kennedy
BOSTON (MarketWatch) -- The assistant majority leader of the Massachusetts state senate has asked biodefense developer Hollis-Eden (HEPH) for information on its radiation sickness drug Neumune, which could be used to treat victims of a terrorist nuclear attack. According to a spokesman for State Sen. Mary Ann Walsh, Walsh has asked Hollis-Eden to supply information on how many doses would be needed to treat residents and commuters in the Greater Boston area, citizens living around the Plymouth, Mass., nuclear power plant, and the state's emergency first responders and guardsmen, a number that would reach well in excess of 1 million. Walsh's office said she plans to present the information, along with projected costs, to the Mass. Senate Ways and Means Committee at the end of the month, when the committee begins the state's budget process. Hollis-Eden confirmed it was working to provide Walsh's office with the requested projections. Hollis-Eden is also in the process of seeking a federal contract for Neumune under the Project Bioshield anti-terrorism initiative.
WHen they announce the news AVST will run hard with the low float.Look at USXP float over a billion shares and it ran 700% a few days.
Nice call MT USXP is up @ .006 now .
I will wait for the RS and let the market digest the overhang shares.Usually the SP will crash after the RS.IMO
Chinese stocks are going crazy today .CESV JADE ,NWD,BNSO,CXTI,.
OXiGENE to Commence a Randomized Clinical Trial in the United States to Evaluate CA4P for the Treatment of Patients with Non Small Cell Lung Cancer (NSCLC)
Business Wire - February 03, 2006 08:00
WALTHAM, Mass., Feb 03, 2006 (BUSINESS WIRE) -- OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN)
-- Combretastatin A4P (CA4P) will be Evaluated with Concurrent Chemoradiotherapy, a Widely-Accepted Treatment Regimen in the United States--
-- Trial Endpoint Targets a One-Year Survival Benefit in Patients with All Histological Types of Unresectable, Stage IIIa/IIIb NSCLC--
-- Distinct Clinical Trials in the US and Europe Could Maximize the Market Opportunity for CA4P in Key Oncology Indication--
OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), a leading developer of biopharmaceutical compounds designed to treat cancer and certain ophthalmologic diseases, today announced that it plans to commence a Phase II clinical trial in the United States for the treatment of Stage IIIa/IIIb Non Small Cell Lung Cancer (NSCLC). The Company will evaluate its lead clinical candidate, Combretastatin A4P (CA4P), in combination with concurrent chemoradiotherapy, a widely accepted standard in the United States for the treatment of patients with all histological types of unresectable Stage IIIa/IIIb NSCLC. The trial will be conducted under OXiGENE's Investigational New Drug (IND) application on file with the United States Food and Drug Administration.
The Phase II clinical trial will commence by enrolling approximately 12 patients to assess the tolerability of the protocol and to establish the recommended dose of intravenously administered CA4P. This trial will be the first in which CA4P is administered to patients in combination with concurrent chemoradiotherapy. In other ongoing clinical trials, CA4P has been paired with chemotherapy or radiation therapy with no observed side effects beyond those typically experienced with either treatment.
The Phase II clinical trial will then proceed as a randomized, open label, multi-center trial that will compare two cohorts of patients -- an investigational group and an active control group. Approximately 66 patients who have not had prior treatment for NSCLC will be randomized 2:1 into the two groups. Patients enrolled in the investigational group will be treated with radiotherapy and seven cycles of chemotherapy plus CA4P, followed by maintenance chemotherapy plus CA4P. The objective of the Phase II clinical trial is to evaluate the survival benefit in patients achieved at one year. The response rate will be evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST).
The announcement of this randomized Phase II clinical trial with CA4P in the United States follows OXiGENE's recent announcement of receipt of regulatory clearance from the Medicines and Healthcare Products Regulatory Agency (MHRA) to commence a Phase III clinical trial of CA4P in the United Kingdom in patients with inoperable Stage IIIb/IV NSCLC, a subset of patients not deemed suitable for curative treatment with concurrent radiotherapy.
"We believe this Phase II clinical trial to be a key stepping stone in the path towards potential commercialization of CA4P for the treatment of NSCLC," commented Frederick Driscoll, President and CEO of OXiGENE. "We expect that the commencement of this trial in the United States, combined with the Phase III clinical trial which we plan to commence in Europe for the treatment of patients with Stage IIIb/IV NSCLC, may provide a springboard for OXiGENE to maximize its registrational opportunities in a key oncology indication, and with standards of therapy most often selected by oncologists for each subset of patients. Strategically, this is a key clinical achievement for the Company."
About Non Small Cell Lung Cancer
Non small cell lung cancer accounts for 75% of all lung cancer,(1) making it the most widespread form of lung cancer. Approximately 350,000 cases are expected to be diagnosed globally each year.(2) Stage IIIa NSCLC is one of the largest growing segments of the disease, due to newer tests that enable earlier detection of the disease.(3), (4) Approximately 56% of patients with Stage IIIa/IIIb live for one year when treated with concurrent radiotherapy.(5)
About Combretastatin A4P (CA4P)